Abstract
The adenylate cyclase (ADCY) superfamily is a group of glycoproteins regulating intracellular signaling. ADCYs act as key regulators in the cyclic adenosine monophosphate (cAMP) signaling pathway and are related to cell sensitivity to chemotherapy and ionizing radiation. Many members of the superfamily are detectable in most chemoresistance cases despite the complexity and unknownness of the specific mechanism underlying the role of ADCYs in the proliferation and invasion of cancer cells. The overactivation of ADCY, as well as its upstream and downstream regulators, is implicated as a major potential target of novel anticancer therapies and markers of exceptional responders to chemotherapy. The present review focuses on the oncogenic functions of the ADCY family and emphasizes the possibility of the mediating roles of deleterious nonsynonymous single nucleotide polymorphisms (nsSNPs) in ADCY as a prognostic therapeutic target in modulating resistance to chemotherapy and immunotherapy. It assesses the mediating roles of ADCY and its counterparts as stress regulators in reprogramming cancer cell metabolism and the tumor microenvironment. Additionally, the well-evaluated inhibitors of ADCY-related signaling, which are under clinical investigation, are highlighted. A better understanding of ADCY-induced signaling and deleterious nsSNPs (p.E1003K and p.R1116C) in ADCY6 provides new opportunities for developing novel therapeutic strategies in personalized oncology and new approaches to enhance chemoimmunotherapy efficacy in treating various cancers.
Introduction
Despite significant advances in targeted therapy and immunotherapy, chemoresistance and radiation resistance remain formidable obstacles in oncology. A primary driver of this resistance is the dysregulation of intracellular signaling pathways. Central to these pathways is cyclic adenosine monophosphate (cAMP), a ubiquitous second messenger that acts as a "switchboard" for cellular behavior. The production of cAMP is primarily governed by the Adenylate Cyclase (ADCY) superfamily of enzymes.
While the general role of cAMP has been recognized for decades, the specific contributions of the ten distinct ADCY isoforms to cancer progression and treatment resistance have remained elusive. This review addresses the critical gap between our fundamental understanding of cAMP and the actionable potential of targeting specific ADCY enzymes to sensitize tumors to conventional therapies.
Methodology and Data Integration
This comprehensive review synthesizes current literature and employs advanced computational (in silico) techniques to evaluate the ADCY family's role in malignancy. The authors utilized a robust bioinformatics pipeline, including tools such as PolyPhen-2, SIFT, I-Mutant3.0, and Mutation Taster, to assess the pathogenicity of 60 known ADCY mutations.
Furthermore, structural homology modeling was conducted to compare wild-type and mutant ADCY6 proteins. This allowed for the visualization of how specific single nucleotide polymorphisms (nsSNPs), such as p.E1003K, physically alter the enzyme's active site. Data were aggregated from several public genomic and clinical databases, including OMIM and HGMD for mutation identification, dbGAP for clinical significance, and ExAC for variant frequency analysis.
Key Insights: Isoform Specificity and Pathogenic Hotspots
A central finding of this research is that the ADCY family is not a monolith; rather, isoform specificity is paramount. For instance, ADCY4 is significantly downregulated in breast cancer, whereas ADCY9 expression is elevated in colon cancer. This heterogeneity suggests that therapeutic modulation of cAMP must be highly targeted to be effective.
The analysis identified specific "pathogenic hotspots," particularly within ADCY6. Mutations such as p.E1003K, p.R1116C, and p.Y992C were flagged as highly deleterious. Structural modeling indicates these mutations reside within the active site, potentially causing a loss of enzymatic activity that disrupts downstream DNA repair mechanisms and apoptotic pathways.
The Link to DNA Repair and Metabolism
A significant discovery is the regulatory link between ADCY-induced cAMP signaling and the XRCC1 protein. By influencing the repair of DNA damage induced by chemotherapy and radiation, ADCY signaling acts as a critical component of the cancer cell's survival toolkit. Furthermore, ADCY plays a role in metabolic reprogramming within the tumor microenvironment, helping cancer cells adapt to physiological stress.
Results and Clinical Implications
The in silico analysis confirmed the high pathogenicity of ADCY6 variants p.E1003K and p.R1116C. From a therapeutic perspective, the review highlights that AC agonists, such as Forskolin, can sensitize triple-negative breast cancer (TNBC) cells to doxorubicin and 5-fluorouracil by inhibiting the ERK pathway. Additionally, ADCY9 expression levels have emerged as a potential prognostic biomarker in colon cancer, where lower levels correlate with improved disease-free survival.
Discussion and Future Directions
While the potential for targeting ADCY is clear, several challenges remain. Most current ADCY inhibitors lack selectivity, leading to significant off-target effects in the heart and brain, including potential memory and motor impairments. Furthermore, the precise molecular mechanisms by which specific ADCY isoforms drive proliferation in various contexts require deeper investigation.
Future research must focus on the development of isoform-specific inhibitors and the validation of nsSNPs as biomarkers for identifying "exceptional responders." Moving toward personalized oncology will require a more nuanced understanding of the ADCY-induced signaling landscape to enhance the efficacy of chemoimmunotherapy.
Summary updated